CAN
Cann Group
Cann Group is an Australian pharmaceutical company focused on cultivating cannabis for medicinal and research purposes. They manufacture medicinal cannabis products, aiming to be a national benchmark for R&D and production processes. The company strives to improve the quality of life for patients through ethical leadership in the emerging medical cannabis industry.
Shorted
About
website
industry
address
Key Metrics
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
Company Overview
AI-generated company summary
Cann Group is an Australian pharmaceutical company focused on cultivating cannabis for medicinal and research purposes. They manufacture medicinal cannabis products, aiming to be a national benchmark for R&D and production processes. The company strives to improve the quality of life for patients through ethical leadership in the emerging medical cannabis industry.
Company History
Cann Group was founded with the goal of becoming a leader in Australia's medicinal cannabis industry. They have established a state-of-the-art flagship Mildura facility. The company focuses on research and development to ensure the supply of quality medicinal cannabis products. Cann Group continues to evolve by adapting to the changing regulatory landscape and market demands.
Competitive Advantages
Cann Group's competitive advantages include: 1) State-of-the-art Mildura facility enabling large-scale cultivation. 2) Focus on research and development to ensure high-quality medicinal cannabis products. 3) Established presence and ethical leadership in the Australian medicinal cannabis market.
Risk Factors
- •Regulatory changes affecting cannabis production and distribution
- •Competition from other medicinal cannabis companies
- •Fluctuations in market demand for medicinal cannabis products
Recent Developments
Last 6 months
Recent developments include a funding update announced on March 18, 2024, and consecutive months of record yield at the Mildura facility as of November 10, 2023. Cann Group also raised $2 million via a convertible securities facility in November 2023. Murray was offered a seat on the AMCA advisory group in February 2024.
Key People
Leadership team at Cann Group
Jenni Pilcher
Chief Executive Officer
Current Chief Executive Officer of Cann Group.
Angelos Borobokas
GM
General Manager at Cann Group.
Ms. Jennifer Lee Pilcher AGIA, BBS, C.A.
CEO, MD & Executive Director
Mr. Steven Notaro BA, J.D.
Head of Legal and Regulatory Affairs & Company Secretary